A significantly reduced leukemia burden was observed in the AML-inoculated leg of mice treated with CXCR4R334X-expressing NK cells compared with mice receiving control or CXCR4-KO NK cells (Figure 2A). This evidence concerns the gene CXCR4 and acute myeloid leukemia.